

LISTING OF CLAIMS

1-51. (Canceled)

52. (Currently amended) A method of delivering an antibody to a subject mammal without triggering an anti-idiotypic response directed against said antibody in said mammal, said method comprising, transplanting a genetically modified mammal cell, which [comprising] comprises (i) a polynucleotide encoding an antibody or fragment thereof, and (ii) a promoter sequence controlling expression of the polynucleotide in the cell, [wherein the] said polynucleotide is expressed and the cell secretes the encoded antibody or fragment thereof such that the antibody or fragment thereof reaches the blood circulation of the subject mammal, and wherein the said cell is a cell not specialized for the production of antibodies and able to a long life in the mammal's subject, preferably at least several months to several years up to until lifetime to the patient.

53. (Previously presented) The method of claim 52, wherein the cell is selected from the group consisting of keratinocytes, hepatocytes, skin fibroblasts, myoblasts, endothelial cells and hematopoietic stem cells.

54. (Canceled)

55. (Previously presented) The method of claim 52, wherein the cell is capable of differentiating into a tissue but retains the ability to secrete the antibody.

56. (Canceled)

57. (Previously presented) The method of claim 52, wherein the antibody is detectable in the blood of the subject mammal.

58-59. (Canceled)

60. (New) The method of claim 52, wherein the antibody produced by cells which are not specialized for the production of antibodies display a thermodynamic and kinetic properties identical to those initially produced by plasmocytes.

61. (New) The method of claim 52, wherein antibody or fragment thereof reaching the blood circulation of a mammal subject is present in a quantity which is therapeutically effective.